contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls {
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      defaultInstrument {
        isin
        id
      }
      id
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


invitation-to-presentation-of-the-q1-report-2024

__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

pageUrl

alternatePageUrls

imgUrl

description

Oncopeptides is a biotech company that develops drugs for difficult-to-treat hematological diseases. The company uses its PDC platform to develop peptide-linked drugs that selectively deliver cytotoxic drugs into cancer cells. The company has drugs in commercialization and several drug candidates under development. Oncopeptide's head office is located in Stockholm.

Oncopeptides

Stockholm – May 21, 2024 – Oncopeptides AB (publ), a biotech company focused on difficult-to-treat cancers, will publish the report for the first quarter of 2024, at 08:00 CET on May 30, 2024...

<div class="mfn-preamble"><p><strong>Stockholm – May 21, 2024 – Oncopeptides AB (publ), a biotech company focused on difficult-to-treat cancers, will publish the report for the first quarter of 2024, at 08:00 CET on May 30, 2024.</strong></p></div><div class="mfn-body"><p>Investors, financial analysts, and media are invited to participate in a webcast and a subsequent Q&amp;A session, at 09:00 CET on May 30.<br>&nbsp;<br>The presentation will be hosted by Sofia Heigis, CEO, together with Henrik Bergentoft, CFO. The webcast will be held in English and published on the website of Oncopeptides – <a rel="noopener" href="http://www.oncopeptides.com">www.oncopeptides.com</a> – in conjunction with the start of the presentation.<br>&nbsp;<br><strong>Information for participants</strong><br>If you wish to participate via webcast please use the link below.<br><a rel="noopener" href="https://ir.financialhearings.com/oncopeptides-q1-report-2024">https://ir.financialhearings.com/oncopeptides-q1-report-2024</a><br>&nbsp;<br>&nbsp;<br>If you wish to participate via teleconference please register on the link below. After registration you will be provided phone numbers and a conference ID to access the conference. You can ask questions verbally via the teleconference.<br>&nbsp;<br><a rel="noopener" href="https://conference.financialhearings.com/teleconference/?id=50048825">https://conference.financialhearings.com/teleconference/?id=50048825</a></p></div><div class="mfn-footer mfn-contacts mfn-ad2e6a7e9211"><p><strong class="mfn-heading-1">For more information, please contact:</strong><br>David Augustsson, Director of IR and Communications, Oncopeptides AB (publ)<br>E-mail: <a rel="noopener" href="mailto:david.augustsson@oncopeptides.com">david.augustsson@oncopeptides.com</a><br>Cell phone: +46 76 229 38 68</p></div><div class="mfn-footer mfn-about mfn-05abf943815f"><p><strong class="mfn-heading-1">About Oncopeptides</strong><br>Oncopeptides is a biotech company focusing on research, development and commercialization of targeted therapies for difficult-to-treat cancers.&nbsp;The company uses its proprietary Peptide Drug Candidate platform (PDC) to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells.&nbsp;</p><p>Pepaxti®&nbsp;(melphalan flufenamide, also called melflufen) has been granted Marketing Authorization, in the European Union, the EEA-countries Iceland, Lichtenstein and Norway, as well as in the UK. Pepaxti is indicated in combination with dexamethasone for the treatment of adult patients with multiple myeloma who have received at least three prior lines of therapies, whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one anti-CD38 monoclonal antibody, and who have demonstrated disease progression on or after the last therapy. For patients with a prior autologous stem cell transplantation, the time to progression should be at least 3 years from transplantation.</p><p>Oncopeptides is developing several new compounds based on its proprietary technology platforms and is listed&nbsp;on Nasdaq Stockholm with the ticker ONCO. For more information see: <a rel="noopener" href="http://www.oncopeptides.com/en">www.oncopeptides.com</a></p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong><br><a rel="noopener" href="https://storage.mfn.se/e057943d-fde4-492d-98b1-72a359549674/invitation-to-presentation-of-the-q1-report-2024.pdf" class="mfn-generated mfn-primary">Invitation to presentation of the Q1 report 2024</a></p></div>

Invitation to presentation of the Q1 report 2024

Probabilities of success in drug development

Return on capital (ROE, ROI, ROIC, RONIC)

Helsinki Stock Exchange is cheap

Drug development investment: Value creation through M&As and licensing agreements

Valuation methods: Valuation multiples

Stay up to date with our newsletter